a Hacettepe University Faculty of Medicine , Department of Pediatric Infectious Diseases , Ankara , Turkey.
b Hacettepe University Faculty of Medicine , Department of Pediatric Infectious Diseases , Ankara , Turkey.
Hum Vaccin Immunother. 2018 Jan 2;14(1):106-110. doi: 10.1080/21645515.2017.1371378. Epub 2017 Nov 7.
The present study aimed to determine the cost of childhood pneumococcal infections under 5 years of age and to provide further data for future health economy studies. Electronic medical records of children diagnosed with meningitis caused by S. pneumoniae and all-cause pneumonia, and acute otitis media (AOM) between January 2013-April 2014 were retrospectively evaluated. Direct costs for the treatments of hospitalized patients (pneumonia and pneumococcal meningitis) including costs of healthcare services consisted of costs of hospital bed, examination, laboratory analyses, scanning methods, consultation, vascular access procedures, and infusion and intravenous treatments. Direct costs for patients (AOM) treated in outpatient setting included constant price paid for the examination and cost of prescribed antibiotics. Indirect costs included cost of work loss of parents and their transportation expenses. Data of 130 children with pneumococcal meningitis (n = 10), pneumonia (n = 53), and AOM (n = 67) were analyzed. The total median cost was €4,060.38 (direct cost: €3,346.38 and indirect cost: €829.18) for meningitis, €835.91 (direct cost: €480.66 and indirect cost: €330.09) for pneumonia, and €117.32 (direct cost: €17.59 and indirect cost: €99.73) for AOM. The medication cost (p = 0.047), indirect cost (p = 0.032), and total cost (p = 0.011) were significantly higher in pneumonia patients aged ≥36 months than those aged <36 months; however, direct cost of AOM were significantly higher in the patients aged <36 months (p = 0.049). Results of the present study revealed that the treatment cost was significantly enhanced for hospitalization and for advanced disease. Thus, preventive actions, mainly vaccination, should be conducted regularly.
本研究旨在确定 5 岁以下儿童感染肺炎球菌的成本,并为未来的卫生经济学研究提供进一步的数据。对 2013 年 1 月至 2014 年 4 月期间被诊断为肺炎链球菌性脑膜炎、所有病因肺炎和急性中耳炎(AOM)的儿童的电子病历进行了回顾性评估。住院患者(肺炎和肺炎球菌性脑膜炎)治疗的直接费用包括医疗服务成本,包括住院床位、检查、实验室分析、扫描方法、咨询、血管通路程序以及输液和静脉治疗的费用。门诊治疗的患者(AOM)的直接费用包括检查的固定价格和规定抗生素的费用。间接费用包括父母的工作损失成本和交通费用。共分析了 130 名患有肺炎球菌性脑膜炎(n = 10)、肺炎(n = 53)和 AOM(n = 67)的儿童的数据。脑膜炎的总中位数费用为 4060.38 欧元(直接费用:3346.38 欧元,间接费用:829.18 欧元),肺炎为 835.91 欧元(直接费用:480.66 欧元,间接费用:330.09 欧元),AOM 为 117.32 欧元(直接费用:17.59 欧元,间接费用:99.73 欧元)。≥36 个月的肺炎患者的药物费用(p = 0.047)、间接费用(p = 0.032)和总费用(p = 0.011)明显高于<36 个月的肺炎患者;然而,<36 个月的 AOM 患者的直接费用明显较高(p = 0.049)。本研究结果表明,住院治疗和疾病严重程度增加显著增加了治疗成本。因此,应定期采取预防措施,主要是接种疫苗。